Research Guide · HGH 191aa

What is HGH 191aa?

A comprehensive examination of recombinant human growth hormone somatropin — molecular structure, receptor pharmacology, and applications in growth-axis research.

Updated September 2026 Research Use Only 12 min read

What is HGH 191aa

Introduction to recombinant human growth hormone as analytical reference standard.

Structure & Identity

HGH 191aa (somatropin) is a synthetic 191-amino acid polypeptide produced via recombinant DNA technology in E. coli or mammalian cell culture. Sequence identical to native human pituitary GH 22 kDa isoform. Single-chain polypeptide with two intramolecular disulfide bonds (Cys-53–Cys-165 and Cys-182–Cys-189). MW ~22,124 Da. Distinct from earlier 192aa methionyl variants now obsolete.

Receptor & Mechanism

HGH 191aa binds the growth hormone receptor (GHR), a single-transmembrane receptor coupled to JAK2/STAT5 signal transduction. Binding induces GHR dimerisation and JAK2 trans-phosphorylation, which phosphorylates STAT5b. Phosphorylated STAT5b translocates to the nucleus and induces hepatic IGF-1 synthesis (~75% of circulating IGF-1) and metabolic gene programmes.

Regulatory Status

FDA-approved for GH deficiency (paediatric/adult), Turner syndrome, Prader-Willi, ISS, AIDS-associated wasting. Commercial products include Genotropin, Humatrope, Norditropin, Nutropin, Serostim. As an analytical reference standard, HGH 191aa is essential for calibrating bioassays, validating GH measurement methods, and studying GHR pharmacology.

Mechanism of Action

Detailed molecular pathways from receptor binding through signal transduction to biological response.

GHR Binding & Dimerisation

HGH 191aa binds GHR on hepatocytes, adipocytes, myocytes, and bone cells. Single HGH molecule binds two GHR monomers, inducing conformational change that brings the cytoplasmic JAK2 kinases into proximity for trans-phosphorylation at activation-loop tyrosines.

JAK2–STAT5 Signal Cascade

Activated JAK2 phosphorylates GHR and the latent transcription factor STAT5b. Phosphorylated STAT5b dimerises and translocates to the nucleus, binding GH response elements in the IGF-1 promoter. Secondary MAPK signalling contributes to proliferative and metabolic responses.

Hepatic IGF-1 Production

Hepatocytes synthesise and secrete IGF-1 in response to GH stimulation. ~75% of circulating IGF-1 is hepatic; remaining 25% is local autocrine/paracrine production in muscle, bone, adipose. IGF-1 acts on IGF-1 receptors throughout the body to mediate growth-promoting and metabolic effects.

Metabolic & Anabolic Effects

HGH directly stimulates lipolysis in adipose tissue via HSL activation. Promotes anabolic effects in skeletal muscle through increased amino acid uptake, mTOR activation, and myogenic gene transcription. In liver, GH promotes gluconeogenic capacity and increases hepatic glucose output (counter-insulin effects). Promotes bone formation via direct GHR signalling and IGF-1.

HGH 191aa vs Related GH-Axis Peptides

Comparison against secretagogues, GHRH analogues, and IGF-1 variants.

Compound

Mechanism

Research Distinction

HGH 191aa (Somatropin)

Direct GHR agonist; recombinant hGH

Direct GH/IGF-1 axis activation; supraphysiological IGF-1; non-pulsatile when exogenous

Tesemorelin

GHRH analogue (44-aa); GHRHR agonist

Preserves pulsatile endogenous GH; FDA-approved for HIV lipodystrophy

CJC-1295

GHRH analogue ± DAC; extended half-life

Sustained non-physiological GH elevation; suited to chronic exposure models

Ipamorelin

GHRP pentapeptide; ghrelin receptor agonist

Parallel GH secretagogue pathway; minimal cortisol/prolactin effects

IGF-1 LR3

Long-acting IGF-1 variant

Bypasses GH axis entirely; permits IGF-1-specific cellular research

Research Context: HGH 191aa is the only direct GH receptor agonist in this comparison, making it irreplaceable for GHR pharmacology, binding kinetics, and direct receptor-mediated cellular response investigation. Unlike GHRH analogues that stimulate endogenous secretion, HGH 191aa provides direct sustained GH signal without HPA-axis involvement — valuable for dissecting JAK2–STAT5 / MAPK signalling in isolation.

Key Research Applications

Primary investigative domains.

GHR Pharmacology & Signal Transduction

HGH 191aa is the gold-standard ligand for GHR binding kinetics, receptor dimerisation, and JAK2-STAT5 activation studies. Researchers map receptor-binding domains, measure binding affinity, study STAT5 phosphorylation dose-response, and characterise downstream MAPK activation. Cell-based assays enable measurement of GH-induced gene transcription (IGF-1, SOCS), critical for validating new GHR antagonists/agonists.

Body Composition & Metabolic Models

In rodent studies, exogenous HGH 191aa investigates mechanisms underlying GH-induced changes in lean mass, adiposity distribution, and metabolic rate. Chronic GH treatment increases muscle protein synthesis, reduces visceral adipose tissue, elevates hepatic glucose production. Essential for studying somatopause, cachexia models, and GH’s role in metabolic disorders.

GH Deficiency & Replacement Models

Animal models of GH deficiency (Snell dwarf mouse, GH-knockout) complemented by HGH 191aa administration to restore signalling and reverse growth failure. Ex-vivo and in-vitro studies using patient-derived cells exposed to HGH 191aa investigate GH sensitivity and GHR expression alterations.

Bone Metabolism & Fracture Healing

HGH 191aa is used in bone research to investigate GH’s anabolic effects on osteoblast function, bone mineral density, and fracture healing. The GH/IGF-1 axis is critical for endochondral bone formation and bone remodelling. Studies establish mechanisms for GH-induced osteoblast differentiation and matrix protein deposition.

Analytical Reference Standard

Essential for validating clinical GH immunoassays (ELISA, RIA, LC-MS), establishing inter-assay consistency, and calibrating bioassays measuring GH-induced IGF-1 production. Standardised reference materials traceable to WHO international GH standards enable measurement accuracy verification across clinical and research settings.

Quick Reference Specifications

Essential biochemical parameters.

P · 01

Nomenclature

Somatropin; recombinant hGH; HGH 191aa

P · 02

Composition

191 amino acids; single-chain; identical to human pituitary GH 22 kDa isoform

P · 03

Molecular Weight

~22,124 Da

P · 04

Disulfide Bonds

Two: Cys-53–Cys-165; Cys-182–Cys-189

P · 05

IU to mg

1 mg ≈ 3 IU (WHO standard); 36 IU ≈ 12 mg

P · 06

Expression System

Recombinant DNA in E. coli or CHO cells

P · 07

Mechanism

GHR agonist; JAK2-STAT5 signalling; hepatic IGF-1 induction

P · 08

Route

Subcutaneous or intramuscular; daily or thrice-weekly typical

P · 09

Storage

Lyophilised: 2–8°C; reconstituted: 2–8°C for 14–28 days; protect from light/freeze-thaw

P · 10

FDA Indications

GH deficiency, Turner syndrome, Prader-Willi, ISS, chronic renal insufficiency, AIDS wasting

Reconstitution & Storage

Best practices for analytical reference standard handling.

Reconstitution Protocol

Reconstitute lyophilised powder with sterile bacteriostatic water. Use aseptic technique with sterile syringes and needles. Allow gentle dissolution at room temperature without vigorous agitation. Reconstituted solution should be clear and colourless to slightly yellow.

Storage & Stability

Lyophilised vials stable for years at 2–8°C. Reconstituted solutions maintain bioactivity 14–28 days at 2–8°C. Protect from direct light. Freeze-thaw cycles cause irreversible aggregation and loss of potency.

Quality Verification

Visual inspection for clarity, colour, particulates. Cloudiness or precipitate indicates degradation. For analytical reference applications, HPLC, mass spectrometry, or SEC should confirm identity, purity, and absence of aggregates before use.

Handling Best Practices

Maintain refrigeration; minimise air exposure; avoid shaking; use fresh sterile needles per withdrawal; document reconstitution date; aliquot small volumes for extended programmes; discard solutions older than 28 days or showing degradation.

Key Published Research

Landmark studies in the history of recombinant growth hormone.

1979

Recombinant hGH

Goeddel and colleagues expressed the human growth hormone gene in E. coli, paving the way for recombinant GH. Recombinant products replaced pituitary-derived GH after it was withdrawn in 1985 over Creutzfeldt–Jakob disease transmission.¹

1990

GH in older men

Six months of GH in men over 60 increased lean body mass and decreased fat mass — a study widely cited in anti-ageing marketing.²

2007

Systematic review

A systematic review of GH in healthy older adults found small changes in body composition but higher rates of adverse events, including soft-tissue oedema, joint pain, carpal tunnel syndrome and gynaecomastia, and concluded GH should not be used as an anti-ageing therapy.³

2011

Adult GHD guideline

The Endocrine Society’s clinical guideline set out diagnosis and management of adult growth hormone deficiency, the main adult indication for somatropin.⁴

Regulatory & Research Status

Where growth hormone stands in 2026.

Prescription-only medicine

Somatropin is a prescription-only medicine in the UK, licensed for specific deficiency and growth disorders.

2020–23

Long-acting GH

Once-weekly long-acting GH products — somapacitan, lonapegsomatropin and somatrogon — have been approved, changing the treatment landscape for GH deficiency.

SPORT

WADA

Growth hormone and its releasing factors remain prohibited at all times on the 2026 WADA list.

Evidence Quality & Limitations

Somatropin has one of the deepest evidence bases of any peptide in these guides, but that evidence concerns defined deficiency states. In people with normal GH secretion, controlled studies show modest body-composition changes, no consistent functional benefit and a higher rate of adverse effects. When using HGH as an analytical standard, verify identity, aggregation state and potency against a traceable reference.

References

Goeddel DV, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 1979;281:544–8. PubMed
Rudman D, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323:1–6. PubMed
Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146:104–15. PubMed
Molitch ME, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587–609. PubMed

⚠ Research Use Only. HGH 191aa is discussed here as an analytical reference standard intended strictly for in-vitro laboratory research and bioassay calibration. Not approved for human consumption, veterinary, or therapeutic use. Users must comply with all applicable regulations.